{"entity":{"type":"insider","cik":"0001326969","url":"/insider/0001326969","json_url":"/insider/0001326969.json","name":"Bedrosian Camille L","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":18,"n_filings":17,"first":"2020-10-16","last":"2026-03-04","span_basis":"filed_date"},"name_variants":[{"name":"Bedrosian Camille L","source":"filing","n_filings":17,"first_seen":"2020-10-16","last_seen":"2026-03-04"}],"transactions":[{"id":5958849,"accession":"0001193125-26-091440","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-091440","line_url":"/filing/0001193125-26-091440#line-1","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6461.0,"shares_display":"6,461","price_per_share":14.5806,"price_display":"14.58","price_state":"stated","total_value":94205.2566,"total_display":"94,205.26","total_whole":"94,205","shares_owned_after":169295.0,"shares_owned_after_display":"169,295","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-04","scope":"insider"},{"id":4846138,"accession":"0001193125-25-306818","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-306818","line_url":"/filing/0001193125-25-306818#line-1","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6580.0,"shares_display":"6,580","price_per_share":14.3493,"price_display":"14.35","price_state":"stated","total_value":94418.394,"total_display":"94,418.39","total_whole":"94,418","shares_owned_after":175756.0,"shares_owned_after_display":"175,756","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-01","filed_date":"2025-12-03","scope":"insider"},{"id":5143132,"accession":"0001193125-25-228339","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-228339","line_url":"/filing/0001193125-25-228339#line-1","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12039.0,"shares_display":"12,039","price_per_share":14.5791,"price_display":"14.58","price_state":"stated","total_value":175517.7849,"total_display":"175,517.78","total_whole":"175,518","shares_owned_after":182336.0,"shares_owned_after_display":"182,336","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-30","filed_date":"2025-10-02","scope":"insider"},{"id":4417472,"accession":"0000950170-25-049567","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-049567","line_url":"/filing/0000950170-25-049567#line-1","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12425.0,"shares_display":"12,425","price_per_share":3.4674,"price_display":"3.47","price_state":"stated","total_value":43082.445,"total_display":"43,082.44","total_whole":"43,082","shares_owned_after":194375.0,"shares_owned_after_display":"194,375","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-31","filed_date":"2025-04-02","scope":"insider"},{"id":2311276,"accession":"0000950170-24-132885","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-132885","line_url":"/filing/0000950170-24-132885#line-1","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5421.0,"shares_display":"5,421","price_per_share":5.5354,"price_display":"5.54","price_state":"stated","total_value":30007.4034,"total_display":"30,007.40","total_whole":"30,007","shares_owned_after":138380.0,"shares_owned_after_display":"138,380","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-02","filed_date":"2024-12-03","scope":"insider"},{"id":2418833,"accession":"0000950170-24-111809","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-111809","line_url":"/filing/0000950170-24-111809#line-1","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11442.0,"shares_display":"11,442","price_per_share":3.1952,"price_display":"3.20","price_state":"stated","total_value":36559.4784,"total_display":"36,559.48","total_whole":"36,559","shares_owned_after":143801.0,"shares_owned_after_display":"143,801","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-30","filed_date":"2024-10-02","scope":"insider"},{"id":7968033,"accession":"0001209191-23-016053","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-016053","line_url":"/filing/0001209191-23-016053#line-2","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3881.0,"shares_display":"3,881","price_per_share":45.25,"price_display":"45.25","price_state":"stated","total_value":175615.25,"total_display":"175,615.25","total_whole":"175,615","shares_owned_after":46720.0,"shares_owned_after_display":"46,720","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-03","scope":"insider"},{"id":6977689,"accession":"0001209191-22-015802","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-015802","line_url":"/filing/0001209191-22-015802#line-2","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2821.0,"shares_display":"2,821","price_per_share":66.62,"price_display":"66.62","price_state":"stated","total_value":187935.02,"total_display":"187,935.02","total_whole":"187,935","shares_owned_after":33938.0,"shares_owned_after_display":"33,938","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-01","filed_date":"2022-03-03","scope":"insider"},{"id":6325760,"accession":"0001209191-22-005838","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-005838","line_url":"/filing/0001209191-22-005838#line-1","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1657.0,"shares_display":"1,657","price_per_share":66.3,"price_display":"66.30","price_state":"stated","total_value":109859.1,"total_display":"109,859.10","total_whole":"109,859","shares_owned_after":36759.0,"shares_owned_after_display":"36,759","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-30","filed_date":"2022-02-01","scope":"insider"},{"id":4956781,"accession":"0001209191-21-060765","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-060765","line_url":"/filing/0001209191-21-060765#line-1","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":359.0,"shares_display":"359","price_per_share":81.14,"price_display":"81.14","price_state":"stated","total_value":29129.26,"total_display":"29,129.26","total_whole":"29,129","shares_owned_after":38416.0,"shares_owned_after_display":"38,416","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-14","filed_date":"2021-10-18","scope":"insider"},{"id":4628570,"accession":"0001209191-21-054542","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-054542","line_url":"/filing/0001209191-21-054542#line-4","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":100.18,"price_display":"100.18","price_state":"stated","total_value":250450.0,"total_display":"250,450.00","total_whole":"250,450","shares_owned_after":38775.0,"shares_owned_after_display":"38,775","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-02","filed_date":"2021-09-02","scope":"insider"},{"id":4624135,"accession":"0001209191-21-054542","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-054542","line_url":"/filing/0001209191-21-054542#line-2","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":100.03,"price_display":"100.03","price_state":"stated","total_value":250075.0,"total_display":"250,075.00","total_whole":"250,075","shares_owned_after":38775.0,"shares_owned_after_display":"38,775","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-01","filed_date":"2021-09-02","scope":"insider"},{"id":4273097,"accession":"0001209191-21-031376","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-031376","line_url":"/filing/0001209191-21-031376#line-1","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":364.0,"shares_display":"364","price_per_share":113.67,"price_display":"113.67","price_state":"stated","total_value":41375.88,"total_display":"41,375.88","total_whole":"41,376","shares_owned_after":38775.0,"shares_owned_after_display":"38,775","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-06","filed_date":"2021-05-10","scope":"insider"},{"id":4825205,"accession":"0001209191-21-027329","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-027329","line_url":"/filing/0001209191-21-027329#line-2","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":109.09,"price_display":"109.09","price_state":"stated","total_value":545450.0,"total_display":"545,450.00","total_whole":"545,450","shares_owned_after":39139.0,"shares_owned_after_display":"39,139","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-15","filed_date":"2021-04-19","scope":"insider"},{"id":4528001,"accession":"0001209191-21-017538","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-017538","line_url":"/filing/0001209191-21-017538#line-3","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4543.0,"shares_display":"4,543","price_per_share":138.18,"price_display":"138.18","price_state":"stated","total_value":627751.74,"total_display":"627,751.74","total_whole":"627,752","shares_owned_after":39139.0,"shares_owned_after_display":"39,139","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-01","filed_date":"2021-03-03","scope":"insider"},{"id":5373612,"accession":"0001209191-21-006787","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-006787","line_url":"/filing/0001209191-21-006787#line-1","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2243.0,"shares_display":"2,243","price_per_share":140.36,"price_display":"140.36","price_state":"stated","total_value":314827.48,"total_display":"314,827.48","total_whole":"314,827","shares_owned_after":33546.0,"shares_owned_after_display":"33,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-30","filed_date":"2021-02-02","scope":"insider"},{"id":4257006,"accession":"0001209191-21-003992","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-003992","line_url":"/filing/0001209191-21-003992#line-2","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":139.18,"price_display":"139.18","price_state":"stated","total_value":3479500.0,"total_display":"3,479,500.00","total_whole":"3,479,500","shares_owned_after":35789.0,"shares_owned_after_display":"35,789","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-15","filed_date":"2021-01-19","scope":"insider"},{"id":2472865,"accession":"0001209191-20-055180","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-055180","line_url":"/filing/0001209191-20-055180#line-1","is_derivative":false,"issuer_cik":"0001326969","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001326969","owner_cik":"0001326969","owner_name":"Bedrosian Camille L","owner_display_name":"Bedrosian Camille L","owner_url":"/insider/0001326969","role":"Officer (EVP and Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (EVP and Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":262.0,"shares_display":"262","price_per_share":88.0,"price_display":"88.00","price_state":"stated","total_value":23056.0,"total_display":"23,056.00","total_whole":"23,056","shares_owned_after":35789.0,"shares_owned_after_display":"35,789","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-14","filed_date":"2020-10-16","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":18,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":18,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":18},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001658551","name":"Amylyx Pharmaceuticals, Inc.","url":"/issuer/0001658551","role":"Officer (Chief Medical Officer)","n_filings":6,"first_seen":"2024-10-02","last_seen":"2026-03-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001515673","name":"Ultragenyx Pharmaceutical Inc.","url":"/issuer/0001515673","role":"Officer (EVP and Chief Medical Officer)","n_filings":11,"first_seen":"2020-10-16","last_seen":"2023-03-03"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001326969","retrieved_at":"2026-08-27T03:42:47+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}